• Home
  • About
  • Works
  • Sustained Curiosity
  • Get in Touch
  Robert Charles Powell, MD, PhD

Robert Charles Powell, MD, PhD

AUTHOR / RESEARCHER / HISTORIAN / CLINICIAN
Latest release: When Death Is NOT Theoretical: The Readiness of the Music Group ‘Queen’ for Living with Freddie Mercury’s Dying [2nd edition, 2018]
​
Picture
Most considerations of Queen and its musical catalogue have been by journalists, but Dr. Powell approaches these questions as an historian and clinician, analyzing fifty-some songs and mobilizing extensive amounts of data to support his conclusions.  — excerpt from description of When Death is NOT Theoretical, Amazon 

2nd ed -- with an Addendum & now an Index -- 40% longer than 1st ed
Contact me
Freddie Mercury  --  Brian May -- Roger Taylor -- John Deacon
                               -- "Bohemian Rhapsody" --
COVID-19 
See below, under "Works." my booklet: 
Pentoxifylline: A Versatile Off-Patent Medication Best Not Overlooked


Some Published Medical Thoughts (as of September 1st, 2020) about
COVID-19 & Pentoxifylline

(a phosphodiesterase 4 inhibitor ) (a production inhibitor of TNF-alpha, IL-6, & IL-2R )
 
Hendry BM, Stafford N, Arnold AD, et al. “Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.” Pharmacol Res Perspect. 2020 Aug;8(4):e00631; https://pubmed.ncbi.nlm.nih.gov/32715661/ .
 
Dalamaga M, Karampela I, Mantzoros CS. “Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.” Metabolism. 2020 Aug;109:154282; https://pubmed.ncbi.nlm.nih.gov/32497535/ .
 
Giorgi M, Cardarelli S, Ragusa F, et al. “Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?”. Int J Mol Sci. 2020 Jul;21(15):5338; https://pubmed.ncbi.nlm.nih.gov/32727145/ .
 
González-Pacheco H, Amezcua-Guerra LM, Sandoval J, Arias-Mendoza “A. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.” Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7494-7496; https://pubmed.ncbi.nlm.nih.gov/32706089/ .
 
Kanthi Y, Knight JS, Zuo Y, Pinsky DJ. “New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.” JCI Insight. 2020 Jul;5(14):140971; https://pubmed.ncbi.nlm.nih.gov/32530438/  .

Bridgewood C, Damiani G, Sharif K, et al. “Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.” Isr Med Assoc J. 2020 Jun;22(6):335-339; https://pubmed.ncbi.nlm.nih.gov/32558435/ .

Powered by Create your own unique website with customizable templates.
  • Home
  • About
  • Works
  • Sustained Curiosity
  • Get in Touch